|
|
|
|
Vol. 15, Issue 10, 4725-4734, October 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratory of Cell Morphogenesis and Tumor Progression, UMR 144 CNRS, Institut Curie, Section de recherche, 75248 Paris Cedex 05, France
Submitted April 23, 2004;
Revised June 17, 2004;
Accepted July 20, 2004
Monitoring Editor: Carl-Henrik Heldin
Fibroblast growth factor (FGF)-1 and -2 have potent biological activities implicated in malignant tumor development. Their autocrine and nonautocrine activity in tumor progression of carcinoma was investigated in the NBT-II cell system. Cells were manipulated to either produce and be autocrine for FGF-1 or -2 or to only produce but not respond to these factors. The autocrine cells are highly invasive and tumorigenic and the determination of specific targets of FGF/fibroblast growth factor receptor (FGFR) signaling was assessed. In vitro studies showed that nonautocrine cells behave like epithelial parental cells, whereas autocrine cells have a mesenchymal phenotype correlated with the overexpression of urokinase plasminogen activator receptor (uPAR), the internalization of E-cadherin, and the redistribution of
-catenin from the cell surface to the cytoplasm and nucleus. uPAR was defined as an early target, whereas E-cadherin and the leukocyte common antigen-related protein-tyrosine phosphatase (LAR-PTP) were later targets of FGF signaling, with FGFR1 activation more efficient than FGFR2 at modulating these targets. Behavior of autocrine cells was consistent with a decrease of tumor-suppressive activities of both E-cadherin and LAR-PTP. These molecular analyses show that the potential of these two growth factors in tumor progression is highly dependent on specific FGFR signaling and highlights its importance as a target for antitumor therapy
* Corresponding author. E-mail address: jacqueline.jouanneau{at}curie.fr.
This article has been cited by other articles:
![]() |
R. Pai, D. Dunlap, J. Qing, I. Mohtashemi, K. Hotzel, and D. M. French Inhibition of Fibroblast Growth Factor 19 Reduces Tumor Growth by Modulating {beta}-Catenin Signaling Cancer Res., July 1, 2008; 68(13): 5086 - 5095. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Huang, Z. Hu, M. Li, Y. Cui, Y. Li, L. Guo, W. Jiang, and S. H. Lu ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity Carcinogenesis, November 1, 2007; 28(11): 2274 - 2281. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Battersby, K.J. Sales, A.R. Williams, R.A. Anderson, S. Gardner, and H.N. Jabbour Seminal plasma and prostaglandin E2 up-regulate fibroblast growth factor 2 expression in endometrial adenocarcinoma cells via E-series prostanoid-2 receptor-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase pathway Hum. Reprod., January 1, 2007; 22(1): 36 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stapelberg, N. Gellert, E. Swettenham, M. Tomasetti, P. K. Witting, A. Procopio, and J. Neuzil {alpha}-Tocopheryl Succinate Inhibits Malignant Mesothelioma by Disrupting the Fibroblast Growth Factor Autocrine Loop: MECHANISM AND THE ROLE OF OXIDATIVE STRESS J. Biol. Chem., July 8, 2005; 280(27): 25369 - 25376. [Abstract] [Full Text] [PDF] |
||||